EquitySector - HealthcareVery High Risk
Direct
NAV (20-Dec-24)
Returns (Since Inception)
Fund Size
₹1,203 Cr
Expense Ratio
1.25%
ISIN
INF789F01TO9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
01 Jan 2013
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+46.78%
+43.28% (Cat Avg.)
3 Years
+23.39%
+21.60% (Cat Avg.)
5 Years
+28.92%
+27.61% (Cat Avg.)
10 Years
+14.38%
+15.16% (Cat Avg.)
Since Inception
+17.27%
— (Cat Avg.)
Equity | ₹1,177.73 Cr | 97.88% |
Others | ₹25.49 Cr | 2.12% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹129.12 Cr | 10.73% |
Cipla Ltd | Equity | ₹69.13 Cr | 5.75% |
Ajanta Pharma Ltd | Equity | ₹58.35 Cr | 4.85% |
Dr Reddy's Laboratories Ltd | Equity | ₹56.54 Cr | 4.70% |
Glenmark Pharmaceuticals Ltd | Equity | ₹47.28 Cr | 3.93% |
Gland Pharma Ltd | Equity | ₹46.28 Cr | 3.85% |
Apollo Hospitals Enterprise Ltd | Equity | ₹40.97 Cr | 3.41% |
Fortis Healthcare Ltd | Equity | ₹40.32 Cr | 3.35% |
Procter & Gamble Health Ltd | Equity | ₹38.31 Cr | 3.18% |
Divi's Laboratories Ltd | Equity | ₹37.95 Cr | 3.15% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹37.14 Cr | 3.09% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹36 Cr | 2.99% |
Alkem Laboratories Ltd | Equity | ₹35.56 Cr | 2.96% |
Suven Pharmaceuticals Ltd | Equity | ₹35.41 Cr | 2.94% |
Aurobindo Pharma Ltd | Equity | ₹31.57 Cr | 2.62% |
Caplin Point Laboratories Ltd | Equity | ₹30.75 Cr | 2.56% |
Torrent Pharmaceuticals Ltd | Equity | ₹28.26 Cr | 2.35% |
Emcure Pharmaceuticals Ltd | Equity | ₹27.3 Cr | 2.27% |
Metropolis Healthcare Ltd | Equity | ₹24.48 Cr | 2.03% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹24.46 Cr | 2.03% |
Net Current Assets | Cash | ₹24.12 Cr | 2.00% |
Zydus Lifesciences Ltd | Equity | ₹23.69 Cr | 1.97% |
Marksans Pharma Ltd | Equity | ₹20.57 Cr | 1.71% |
Jupiter Life Line Hospitals Ltd | Equity | ₹20.38 Cr | 1.69% |
Sequent Scientific Ltd | Equity | ₹20.33 Cr | 1.69% |
Pfizer Ltd | Equity | ₹19.83 Cr | 1.65% |
Windlas Biotech Ltd | Equity | ₹18.97 Cr | 1.58% |
Vijaya Diagnostic Centre Ltd | Equity | ₹17.52 Cr | 1.46% |
Ami Organics Ltd | Equity | ₹17.14 Cr | 1.42% |
Syngene International Ltd | Equity | ₹16.93 Cr | 1.41% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹15.43 Cr | 1.28% |
Ipca Laboratories Ltd | Equity | ₹15.43 Cr | 1.28% |
Concord Biotech Ltd | Equity | ₹14.21 Cr | 1.18% |
Alembic Pharmaceuticals Ltd | Equity | ₹13.16 Cr | 1.09% |
Indegene Ltd | Equity | ₹12.43 Cr | 1.03% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹11.48 Cr | 0.95% |
Orchid Pharma Ltd | Equity | ₹11.17 Cr | 0.93% |
Rainbow Childrens Medicare Ltd | Equity | ₹9.83 Cr | 0.82% |
Poly Medicure Ltd | Equity | ₹9.56 Cr | 0.79% |
Jubilant Pharmova Ltd | Equity | ₹5.79 Cr | 0.48% |
Star Health and Allied Insurance Co Ltd | Equity | ₹4.7 Cr | 0.39% |
Global Health Ltd | Equity | ₹4.01 Cr | 0.33% |
364 Days T - Bill- 06/02/2025 | Bond - Gov't/Treasury | ₹1.28 Cr | 0.11% |
Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.09 Cr | 0.01% |
Large Cap Stocks
32.05%
Mid Cap Stocks
26.25%
Small Cap Stocks
36.36%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,155.89 Cr | 96.07% |
Basic Materials | ₹17.14 Cr | 1.42% |
Financial Services | ₹4.7 Cr | 0.39% |
Standard Deviation
This fund
15.68%
Cat. avg.
15.68%
Lower the better
Sharpe Ratio
This fund
0.97
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Since May 2022
ISIN INF789F01TO9 | Expense Ratio 1.25% | Exit Load 1.00% | Fund Size ₹1,203 Cr | Age 11 years 11 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹32.33 Cr | 47.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹854.32 Cr | 39.5% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹854.32 Cr | 37.6% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹42.05 Cr | 43.4% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹217.92 Cr | 47.7% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹217.92 Cr | 44.9% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2742.91 Cr | 43.0% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2742.91 Cr | 40.9% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹840.57 Cr | 40.1% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.39 Cr | 42.4% |
Total AUM
₹3,24,111 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk